Compare Moderna, Inc. (MRNA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Moderna, Inc. is far larger — about 9.3× Global X NASDAQ 100 Covered Call ETF's market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 2,913,938). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| MRNA | QYLD | |
|---|---|---|
Market Cap | $78.65B | $8.49B |
Volume | 37,373,437 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $225.00 | $18.69 |
52-Week Low | $22.36 | $16.70 |
Typical Hold Time | 59 Days | 51 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
QYLD trades at $18.66, showing minimal daily movement with a slight decline of -0.11%. The ETF maintains a consistent monthly dividend distribution of $0.18 per share, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including overbought RSI readings. Recent news highlights QYLD's high yield strategy but raises concerns about long-term capital erosion and tax implications.
QYLD offers high monthly income through covered call strategies but faces significant risks from capped upside potential and principal erosion. The ETF's distribution sustainability depends on Nasdaq volatility, with recent articles warning about declining option premiums. Investors should weigh the trade-off between immediate income and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
